In addition, we determined that the sPD-L1 level increased for IMDC prognostic groups in the population of patients with metastatic CCRCC, and was also associated with the clinical response of patients with metastatic CCRCC receiving systemic therapy. This evidence concerns the gene SPDL1 and nonpapillary renal cell carcinoma.